Coeptis Therapeutics logo

Coeptis TherapeuticsNASDAQ: COEP

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

17 December 2020

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A
$7.89 M
-93%vs. 3y high
16%vs. sector
-vs. 3y high
-vs. sector
-95%vs. 3y high
51%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Tue, 19 Nov 2024 21:22:08 GMT
$0.19-$0.00(-2.09%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

COEP Latest News

Coeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical Development
prnewswire.com07 November 2024 Sentiment: POSITIVE

Study results demonstrate the safety and feasibility of adoptive immunotherapy using allogeneic off-the-shelf NK cells in hospitalized patients with COVID at high risk for progression of disease DVX201, the first allogeneic NK cell therapy derived from pooled donor cord blood CD34+ cells, was administered to 9 patients with no dose limiting toxicities, cytokine release syndrome or infusion toxicities WEXFORD, Pa. , Nov. 7, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, today announced that results from their Phase 1 study evaluating DVX201, an allogeneic natural killer (NK) cell therapy, for the treatment of patients hospitalized with COVID-19 has been accepted for publication in Molecular Therapy Methods and Clinical Development.

Coeptis Therapeutics Expands License Agreement with Deverra to Include Pandemic Preparedness, and Emergency Use
prnewswire.com24 October 2024 Sentiment: POSITIVE

WEXFORD, Pa. , Oct. 24, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, today announced the expansion of its license agreement with Deverra Therapeutics Inc. ("Deverra"), broadening the potential applications of its allogeneic natural killer (NK) cell technology.

Coeptis Therapeutics Closes on $4.3 Million of Series A Preferred Offering
prnewswire.com20 June 2024 Sentiment: POSITIVE

Bolsters Company's Corporate Mission Financing Led by Board Member and Priced at Premium to Market Price WEXFORD, Pa. , June 20, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, is pleased to announce that it has closed on $4.3 million in a financing led by CJC Investment Trust, an entity controlled by board member Christopher Calise.

Why Is Coeptis Therapeutics (COEP) Stock Up 14% Today?
InvestorPlace27 March 2023 Sentiment: POSITIVE

Coeptis Therapeutics (NASDAQ: COEP ) stock is climbing higher on Monday despite a lack of news from the drug company. Investors searching for the reason why COEP stock is up today won't find much news.

What type of business is Coeptis Therapeutics?

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical company. It is developing cell therapy platforms for cancer, autoimmune, and infectious diseases that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Its product portfolio and rights are licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, natural killer cell therapy technology. The company is also developing a multi-antigen CAR T technology licensed from the University of Pittsburgh, and the GEAR cell therapy and companion diagnostic platforms, which are developing with VyGen-Bio and medical researchers at the Karolinska Institute. Its Product Pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

What sector is Coeptis Therapeutics in?

Coeptis Therapeutics is in the Healthcare sector

What industry is Coeptis Therapeutics in?

Coeptis Therapeutics is in the Biotechnology industry

What country is Coeptis Therapeutics from?

Coeptis Therapeutics is headquartered in United States

When did Coeptis Therapeutics go public?

Coeptis Therapeutics initial public offering (IPO) was on 17 December 2020

What is Coeptis Therapeutics website?

https://coeptistx.com

Is Coeptis Therapeutics in the S&P 500?

No, Coeptis Therapeutics is not included in the S&P 500 index

Is Coeptis Therapeutics in the NASDAQ 100?

No, Coeptis Therapeutics is not included in the NASDAQ 100 index

Is Coeptis Therapeutics in the Dow Jones?

No, Coeptis Therapeutics is not included in the Dow Jones index

When was Coeptis Therapeutics the previous earnings report?

No data

When does Coeptis Therapeutics earnings report?

Next earnings report date is not announced yet